SMC has accepted mepolizumab as add-on treatment for severe refractory eosinophilic asthma in children >6yrs. Use is restricted to those who have >150cells/microlitre eosinophils at initiation and >4 exacerbations in preceding year or receiving maintenance oral corticosteroids.